Philip Greenberg

Philip Greenberg is a pioneer in antigen-specific adoptive T cell therapy at Fred Hutchinson Cancer Center, having developed WT1-targeted TCR-T cell therapy for acute myeloid leukemia that has shown promising clinical activity in preventing post-transplant relapse. His four decades of work on understanding how T cells recognize and kill cancer cells has provided fundamental insights that inform modern TCR-T cell therapy design. He has made seminal contributions to the identification of tumor-associated antigens and the development of methods to generate antigen-specific T cells for clinical use.